Biostem Technologies Inc
OTC:BSEM
Biostem Technologies Inc
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.
Revenue Decline: Q3 revenue fell to $10.5 million from $11 million in Q2 and $18.4 million a year ago, mainly due to pricing pressures in the current reimbursement environment.
Strong Product Demand: Product sales volume rose 40% versus Q2, showing robust underlying demand despite reduced selling prices.
Profitability Maintained: BioStem delivered its seventh consecutive quarter of positive adjusted EBITDA and kept gross margins among the industry's best.
Progress on Uplisting: Restated financials have been released and audited financials are expected by end of Q1 2026, with a NASDAQ uplisting targeted for mid-2026.
Market Expansion: The company is expanding into the VA and Medicaid markets and preparing for the 2026 reimbursement reform, positioning itself for growth.
Reimbursement Change Impact: The shift to a flat $127 per square centimeter reimbursement in 2026 is expected to level the playing field and benefit BioStem's value proposition.
